2008-07-02 16:33:16 -
www.companiesandmarkets.com adds new report - Regeneron Pharmaceuticals Inc - Premium Company Profile www.companiesandmarkets.com/Summary-Company-Profile/Regeneron-Ph ..
Introduction
Regeneron Pharmaceuticals is a biopharmaceutical company mainly focused on the development and commercialization of products for oncology, age-related macular degeneration (AMD), and autoimmune diseases. The company is developing its drugs using its Trap technology, which is designed to block key cytokine targets in order to treat disease.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed
business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Regeneron Pharmaceuticals discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.
The company derives all of its revenues from contract manufacturing, research and development payments from collaborators and licensing of products. Its total revenues increased at a CAGR of 30% during 2002-2006, from $22 million to $63 million.
Regeneron Pharmaceuticals´s total revenues are forecast to increase at a CAGR of 57% from $51 million to $308 million during 2006-2010, representing an absolute growth of +$257 million. The increase in contract and collaborative revenues is due to the advancement of product candidates under collaborations with Bayer Healthcare and Sanofi-Aventis.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
